← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in ovarian carcinoma: O43820

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
November 17, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — O43820 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in ovarian carcinoma.

Background

O43820 is a putative protein target identified in ovarian carcinoma, a malignancy with significant unmet therapeutic needs. Initial expression profiling indicates that O43820 may be differentially expressed in ovarian carcinoma tissues compared to normal counterparts. While the biological role of O43820 in ovarian cancer remains to be elucidated, its expression pattern suggests potential involvement in disease pathogenesis, making it a candidate for further experimental validation.

Data-mining rationale

This candidate emerged from a systematic cross-referencing of UniProt’s reviewed human protein entries annotated for "ovarian carcinoma" with a comprehensive set of 686 microarray datasets from the NCBI Gene Expression Omnibus (GEO). Several ovarian carcinoma-related datasets (GDS:200333343, GDS:200322784, GDS:200301530, GDS:200319500, GDS:200315735) showed expression signals for O43820. Notably, no Phase 1 or later clinical trials targeting O43820 were identified in the current clinical landscape, indicating that this protein remains an underexplored target in ovarian carcinoma.

Why prior analyses may have missed this

Many of the GEO datasets analyzed were generated before the widespread adoption of modern empirical-Bayes statistical methods such as limma, which enhance the detection of differentially expressed genes by improving statistical power and controlling false discovery rates. Earlier analyses may have employed less rigorous statistical approaches without appropriate multiple-testing correction, potentially resulting in false negatives and overlooking candidates like O43820. Re-analysis using contemporary bioinformatics methods could reveal more robust evidence supporting O43820’s differential expression and relevance in ovarian carcinoma.

Reasoning for further validation

To evaluate the putative role of O43820 in ovarian carcinoma and its potential as a therapeutic target, the following experimental approaches are recommended:

  1. Re-analysis of GEO datasets: Apply limma with Benjamini-Hochberg false discovery rate correction (FDR < 0.05) to confirm differential expression of O43820 in ovarian carcinoma versus normal tissue samples.
  1. Independent cohort validation: Perform quantitative PCR (qPCR) on an independent set of ovarian carcinoma and matched normal tissues to validate O43820 transcript levels.
  1. Tissue specificity assessment: Examine O43820 expression across normal tissues using databases such as GTEx and the Human Protein Atlas to understand its baseline distribution and potential off-target effects.
  1. Pathway and interaction mapping: Utilize protein interaction resources like STRING and OmniPath to contextualize O43820 within molecular pathways relevant to ovarian carcinoma biology.
  1. Druggability evaluation: If expression and pathway analyses support O43820’s candidacy, investigate druggability through databases such as DGIdb and ChEMBL to identify potential modulators.

These steps will provide a structured framework to validate O43820 as a putative ovarian carcinoma target and inform subsequent preclinical research.


© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications